GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-10-18|

Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea

by GeneOnline
Share To

GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ — Zhiyi Biotech announced that FDA has approved the Company’s Investigational New Drug (IND) application to develop SK10 (Inactivated Bacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Zhiyi Biotech to conduct its Phase 1 clinical trial in the U.S.


It’s noteworthy that it is the world’s first IND application of live biotherapeutic products (LBPs) with CID as an indication. SK10, the first Bacteroides fragilis-based LBP that obtained FDA IND approval, is also the first LBP of Next-generation Probiotics in China that approved for clinical trial by FDA. Moreover, Zhiyi Biotech becomes the first company in China to advance inactivated preparation of LBP to the clinical stage. This achievement is an essential milestone for Zhiyi, signifying that Zhiyi has fully penetrated the technical and registration pathway of pre-clinical development of LBP to both FDA and NMPA.

SK10, an inactivated Bacteroides fragilis-based LBP, has shown significant efficacy on CID models. Pre-clinical studies have indicated that SK10 can reduce the toxicity of chemotherapeutic drugs towards intestinal epithelial cells, regulate the expression of apoptosis-related proteins, reduce inflammatory cytokines, and enhance mucosal barrier function, thereby effectively inhibit the inflammatory response of intestinal epithelial cells induced by chemotherapy and associated diarrhea symptoms. Meanwhile, this preparation has better safety for cancer patients and is more convenient for commercialization.

About Chemotherapy-induced Diarrhea (CID):

Cytotoxic drugs or targeted therapy can cause drug-associated diarrhea. Data shows that the overall incidence of diarrhea caused by 5-fluorouracil and irinotecan is of 50-80%, whilst it caused by EGFR inhibitors such as afatinib, neratinib and pyrotinib is of 75-90%. However, available drugs for CID are limited. For example, loperamide, as a short-term symptomatic treatment, and octreotide, an intravenous/subcutaneous injection, serious adverse effects have been reported for both drugs. Hence the need for effective drugs is urgent.

About Us:

Guangzhou Zhiyi Biotechnology Co., Ltd. , as clinical-stage biotech leading in LBPs in China , is committed to the research and development of LBPs, based on the next generation probiotics (NGPs). It has built up a complete technical and industrial platform, covering from the isolation and identification of new functional strains to the development of innovative products.

For more information, please visit https://www.zypharm.com.cn
or  contact: [email protected]

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top